NCT00353964Unknown2 期
A Multi-Center, Randomized, Double Masked, Placebo and Active Controlled, Parallel-Group Study Evaluating the Safety and Efficacy of rEV131 2.5 Mg/mL, rEV131 1.25 Mg/mL, rEV131 0.625 Mg/mL, for the Treatment of Ocular Inflammation After Cataract Surgery
Evolutec Group2 个研究点 分布在 1 个国家开始时间: 2006年7月19日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 试验地点
- 2
研究概览
简要总结
The purpose of this study is to evaluate the safety and effectiveness of three concentrations of rEV131, a new investigational anti-inflammatory agent, compared to placebo (an inactive substance) and an FDA approved anti-inflammatory agent in patients with ocular inflammation who have undergone cataract extraction with intra-ocular lens implantation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •be male or female who has undergone unilateral cataract extraction by phacoemulsification (PHACO) method with implantation of a posterior chamber intraocular lens
排除标准
- •have unstable glaucoma
- •have an active bacterial and/or viral infection
- •use any ocular or systemic anti-inflammatory agents within 1 week prior to enrollment and for the duration of the study.
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHTGlaucoma and Ocular HypertensionNCT01654484Santen Inc.60
已完成
2 期
Efficacy and Safety of Different Concentrations of Mapracorat Ointment Over 4 Weeks in Atopic Dermatitis (AD)EczemaAtopic DermatitisNCT01359787Bayer197
已完成
2 期
Efficacy and Safety of Different Concentrations of ZK245186 in Atopic Dermatitis (AD)Atopic DermatitisNCT01228513Bayer263
已完成
2 期
Safety and Efficacy of a Three-Dose Regimen of an Adenoviral HIV Vaccine (MRKAd5 HIV-1 Gag/Pol/Nef) in HIV Uninfected South African AdultsHIV InfectionsNCT00413725National Institute of Allergy and Infectious Diseases (NIAID)801
已完成
2 期
Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain MedicationBowel DysfunctionConstipationNCT00101998Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)233